With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
Subscribe To Our Newsletter & Stay Updated
